SDHBmutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma

SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma

(2013) Eric Letouzé et al.   CANCER CELL

Bone Metastases and Skeletal-Related Events in Patients With Malignant Pheochromocytoma and Sympathetic Paraganglioma

(2013) Montserrat Ayala-Ramirez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma

(2013) Ségolène Hescot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma

(2013) Akiyo Tanabe et al.   Hormones & Cancer

Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) A. Berruti et al.   ANNALS OF ONCOLOGY

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

A SDHB malignant paraganglioma with dramatic response to temozolomide–capecitabine

(2012) Cécile Nozières et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Decade (2001-2010) of Genetic Testing for Pheochromocytoma and Paraganglioma

(2012) A. Buffet et al.   HORMONE AND METABOLIC RESEARCH

An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes

(2012) A.-P. Gimenez-Roqueplo et al.   HORMONE AND METABOLIC RESEARCH

Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas

(2011) Montserrat Ayala-Ramirez et al.   CANCER

Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma

(2011) Nelly Burnichon et al.   HUMAN MOLECULAR GENETICS

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

(2011) James C. Yao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients

(2011) Feng Feng et al.   JOURNAL OF UROLOGY

Performance of18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (≥10%) Well-Differentiated Endocrine Carcinoma Staging

(2010) Ronan Abgral et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators

(2010) Montserrat Ayala-Ramirez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Utility of Temozolomide in the Treatment of Malignant Paraganglioma: A Preliminary Report

(2009) E. L. Bravo et al.   HORMONE AND METABOLIC RESEARCH

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

Genome-wide DNA methylation profiling using Infinium®assay

(2009) Marina Bibikova et al.   Epigenomics

Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine

(2008) Hui Huang et al.   CANCER

O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

(2008) M. H. Kulke et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor Scintigraphy

(2008) S. Leboulleux et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM